SIGN UP for the
LI2DAY Email Newsletter!




 

Breast Cancer and Fertility: Know Your Options

By Stephanie Sciara-Glaser

Vice President

Long Island 2 Day Walk To Fight Breast Cancer, Inc.

When a woman is diagnosed with breast cancer, she faces many difficult questions. The diagnosis and efforts to find the best doctors and the best treatments can be overwhelming. She may be unsure about what the cancer will mean to her future. What if she was thinking of having a baby before she was diagnosed? What options exist that will allow a woman to receive the most effective treatment for her cancer while preserving her fertility? More than 11,000 women under the age of forty are diagnosed with breast cancer in the U.S. each year and face this dilemma.

When oncologists determine a course of treatment for breast cancer patients, consideration is first given to life saving measures followed by quality of life concerns. With the growing number of cancer survivors in the United States, greater attention is being given to quality of life concerns. Until recently, fertility preservation was rarely a consideration in treating breast cancer patients. Because oncologists are trained to provide the best cancer treatment available -- not necessarily in light of fertility options -- patients interested in seeking information on fertility need to be proactive. "A patient needs to say to herself, 'What do I want in the future' and ask the doctor, 'What's this treatment going to do with my future plans for fertility?'" says Ann Partridge, MD, MPH, breast oncologist and instructor at Harvard School of Medicine in Boston. She suggests getting a third or even fourth opinion, ideally from doctors in different specialties -- oncology, reproductive endocrinology, gynecology -- since each will provide a unique perspective.

How breast cancer affects fertility will depend mostly on three variables: the type of treatment required, the stage of the diagnosis, and the patient’s age. If a patient needs only surgery and radiation without chemotherapy, the treatment should have no impact on future fertility. The more advanced the cancer upon detection, the greater likelihood that chemotherapy, which affects the whole body, will be used to treat it. Breast cancer patients treated with chemotherapy are very likely to develop premature ovarian failure or early menopause. Chemotherapy works by utilizing various drugs to destroy the cancer cells and hinders the division of the cells. While it is an effective form of treatment, it is also the treatment most likely to damage fertility. Because estrogen plays a role in the development of breast cancer, part of the chemotherapy’s role in treatment is to interfere with the production of estrogen. As a result, almost four out of five women treated with cyclophosphamide will develop ovarian failure, according to Kutluk Oktay, MD, assistant professor at Cornell's Center for Reproductive Medicine and Infertility. If you're 30, your fertility is already declining. With chemotherapy, you add on a few more biological years and chemotherapy has been known to cause the early onset of menopause.

Fertility preservation options are specific to an individual patient, and will depend on how long she is able to safely delay the start of treatment, her age, and whether she has a partner or access to donor sperm. Freezing embryos (fertilized eggs) created by in vitro fertilization (IVF) is the most widely used and effective method, but there are potential downsides. IVF takes three to four weeks, a delay in cancer treatment that, depending on the stage and type of cancer, patients may or may not be able to afford. Sperm -- either from a partner or donor -- must be made available immediately to fertilize the eggs. And IVF is expensive -- anywhere from $10,000 to $14,000 per cycle. However, the success rate is as high as 40%.

Other methods of fertility preservation are experimental but show promise. Egg freezing, which applies the same concept as embryo freezing, has proven less effective -- most likely because eggs are smaller, and less hardy, than embryos. There's also ovarian suppression during treatment (GnRH AnalogTtreatment) which protects ovaries to some degree from the chemical assault precipitated by chemotherapy by administering hormones to suppress ovarian activity and create temporary menopause.  Freezing entire strips of ovarian tissue is a third technique under investigation; it involves surgically removing, storing, and later replacing the tissue in another part of the body. At this time, seven live births have been published in peer-reviewed journals using various methods of transplanted ovarian tissue.


Dr. Teresa Woodruff, the leading fertility researcher at Northwestern University's Feinberg School of Medicine coined the term Oncofertility to describe a new discipline where cancer treatment and fertility health intersect. The Feinberg School of Medicine has launched the Oncofertility Consortium, an interdisciplinary team of oncologists, fertility experts, scientists, social workers, engineers, educators, and medical ethicists to conduct a thorough examination of the scientific, medical, psychological, legal and ethical issues surrounding infertility and cancer. This group continues to engage in clinical research, but also focuses their attention on creating a new generation of patient navigators to ensure that a woman not only fully understands the risks to her fertility by specific treatments, but also understands the available alternatives. The establishment of the National Fertility Hotline will route breast cancer patients to an appropriate site near the home so treatment won’t be delayed while the patient seeks fertility preservation options.

Hopefully, this initiative and others like it will serve as a model for the development of an interdisciplinary approach to fertility issues throughout the country that will usher in a new era in the treatment of women with breast cancer.

For additional information and resources please visit: http://oncofertility.northwestern.edu
or call the Hotline at: 1-866-708-3378